Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (46)	3/18/2002 8:34:20 PM
From: tuck	Read Replies (1) \| Respond to of 510

As for LumiCyte's complaint, the overview mact cites (apparently courtesy of SG Cowen) in the subject post suggests it has to do with the Biomarker Discovery Centers. This old PR gives a little insight as to what they do: >>FREMONT, California, March 13, 2001 -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH) today announced the opening of a Biomarker Discovery Center in Malvern, Pennsylvania. This Biomarker Discovery Center, conveniently located in the East Coast corridor of pharmaceutical and biotechnology companies, is dedicated to proteomics research and protein biomarker discovery including differential protein expression, protein characterization, assay development and validation, and protein interaction studies utilizing Ciphergen’s ProteinChip® System and Arrays. The first project undertaken by the Biomarker Discovery Center is a clinical stratification pilot study on behalf of a major multinational pharmaceutical company. In addition, this center will provide advanced technical support to Ciphergen’s cancer biomarker discovery collaboration with the Johns Hopkins School of Medicine. "The opening of this center is the next step in our providing advanced proteomics services to our pharmaceutical and biotechnology clients," noted William Rich, President and CEO of Ciphergen. "In particular, we see a major opportunity in using our ProteinChip System to perform differential protein expression analysis to discover biomarkers that may have major applications in pre-clinical and clinical drug development." The Philadelphia Biomarker Discovery Center will be managed by Larry D. McClain, Ph.D. Dr. McClain joined Ciphergen in March 2000 and has over 18 years of senior management-level experience in the clinical diagnostic and biotechnology industry. His previous corporate position was Vice President of Research and Development at Centocor Diagnostics. In addition to Dr. McClain, the center will be staffed initially by two Research Scientists and will be equipped with the current and next-generation ProteinChip System and Arrays. Ciphergen has recently developed an interface for two of the industry’s leading tandem MS systems and will be housing one such system in the center as part of Ciphergen’s advanced protein identification capability.<< snip The TOF/TOF is for sequencing the proteins of interest that the SELDI chips turn up. I am not seeing LumiCyte's position that these activities constitute any breach. Are you? BTW, CIPH is also presenting at the Society of Toxicology meeting going on now (toxicology.org). I can't get the itinerary planner/abstract viewer to work; the browser just sits there. Maybe I have to be registered. Interesting vis a vis the toxicogenomics angle you mentioned. Cheers, Tuck